Evaluation of the βLACTA Test, a Novel Commercial Chromogenic Test for Rapid Detection of Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates

Laurent, Terry; Huang, Te-Din; Bogaerts, Pierre; Glupczynski, Youri

doi:10.1128/jcm.00524-13

Cited by 10 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with published data with respect to the low sensitivity of BLT in the detection of plasmid-encoded (CMY, DHA) or overproduced AmpC -lactamases(10,11). In contrast, K. oxytoca isolates with high-level expression of their chromosome-encoded β-lactamase were previously reported as being BLT-positive(10).…”

supporting

confidence: 94%

See 1 more Smart Citation

Early detection with the β-LACTA™ test of extended-spectrum β-lactamase–producing Enterobacteriaceae in blood cultures

Walewski

Podglajen

Lefeuvre

et al. 2015

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

supporting

confidence: 94%

“…BLT can be applied directly to urine sediments (11). Recently, the test has been shown to detect ceftazidimenon-susceptible isolates of Pseudomonas aeruginosa with predictive negative and positive values of respectively 99% and 100% (12).…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Early detection with the β-LACTA™ test of extended-spectrum β-lactamase–producing Enterobacteriaceae in blood cultures

Walewski

Podglajen

Lefeuvre

et al. 2015

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

“…However antimicrobial susceptibility testing is also essential for selecting the optimal treatment. Rapid resistance testing methods have been introduced in clinical microbiology laboratories for the detection of third generation cephalosporin-resistant Enterobacteriaceae (EB) and Pseudomonas aeruginosa or for the detection of methicillin resistance in Staphylococcus aureus [ 10 , 11 , 12 , 13 ]. These partial susceptibility tests have been validated for their diagnostic performance although their clinical impact has not been thoroughly assessed.…”

Section: Introductionmentioning

confidence: 99%

Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

et al. 2016

Self Cite

View full text Add to dashboard Cite

Shortening the turn-around time (TAT) of positive blood culture (BC) identification (ID) and susceptibility results is essential to optimize antimicrobial treatment in patients with sepsis. We aimed to evaluate the impact on antimicrobial prescription of a modified workflow of positive BCs providing ID and partial susceptibility results for Enterobacteriaceae (EB), Pseudomonas aeruginosa and Staphylococcus aureus on the day of BC positivity detection. This study was divided into a pre-intervention period (P0) with a standard BC workflow followed by 2 intervention periods (P1, P2) with an identical modified workflow. ID was performed with MALDI-TOF MS from blood, on early or on overnight subcultures. According to ID results, rapid phenotypic assays were realized to detect third generation cephalosporin resistant EB/P. aeruginosa or methicillin resistant S. aureus. Results were transmitted to the antimicrobial stewardship team for patient’s treatment revision. Times to ID, to susceptibility results and to optimal antimicrobial treatment (OAT) were compared across the three study periods. Overall, 134, 112 and 154 positive BC episodes in P0, P1 and P2 respectively were included in the analysis. Mean time to ID (28.3 hours in P0) was reduced by 65.3% in P1 (10.2 hours) and 61.8% in P2 (10.8 hours). Mean time to complete susceptibility results was reduced by 27.5% in P1 and 27% in P2, with results obtained after 32.4 and 32.6 hours compared to 44.7 hours in P0. Rapid tests allowed partial susceptibility results to be obtained after a mean time of 11.8 hours in P1 and 11.7 hours in P2. Mean time to OAT was decreased to 21.6 hours in P1 and to 17.9 hours in P2 compared to 36.1 hours in P0. Reducing TAT of positive BC with MALDI-TOF MS ID and rapid susceptibility testing accelerated prescription of targeted antimicrobial treatment thereby potentially improving the patients’ clinical outcome.

show abstract

“…Preliminary results suggested that this test is reliable for the detection of 3GC-resistant (3GC-R) Enterobacteriaceae (14). The test was recently evaluated in Pseudomonas aeruginosa to detect resistance to ceftazidime and was found sensitive (95%) and specific (87%) for this purpose (15). Here we report the result of a prospective multicenter study aiming at evaluating the performances of the BLT to rapidly detect resistance to 3GC in clinical isolates of Enterobacteriaceae.…”

mentioning

confidence: 99%

Evaluation of the βLacta Test, a Rapid Test Detecting Resistance to Third-Generation Cephalosporins in Clinical Strains of Enterobacteriaceae

et al. 2013

Self Cite

View full text Add to dashboard Cite

h For decades, third-generation cephalosporins (3GC) have been major drugs used to treat infections due to Enterobacteriaceae; growing resistance to these antibiotics makes the rapid detection of such resistance important. The ␤Lacta test is a chromogenic test developed for detecting 3GC-resistant isolates from cultures on solid media within 15 min. A multicenter prospective study conducted in 5 French and Belgian hospitals evaluated the performance of this test on clinical isolates. Based on antibiotic susceptibility testing, strains resistant or intermediate to cefotaxime or ceftazidime were classified as 3GC resistant, and molecular characterization of this resistance was performed. The rates of 3GC resistance were 13.9% (332/2,387) globally, 9.4% in Escherichia coli (132/1,403), 25.6% in Klebsiella pneumoniae (84/328), 30.3% in species naturally producing inducible AmpC betalactamases (109/360), and 5.6% in Klebsiella oxytoca and Citrobacter koseri (7/124). The sensitivities and specificities of the ␤Lacta test were, respectively, 87.7% and 99.6% overall, 96% and 100% for E. coli and K. pneumoniae, and 67.4% and 99.6% for species naturally producing inducible AmpC beta-lactamase. False-negative results were mainly related to 3GC-resistant strains producing AmpC beta-lactamase. Interestingly, the test was positive for all 3GC-resistant extended-spectrum beta-lactamaseproducing isolates (n ‫؍‬ 241). The positive predictive value was 97% and remained at >96% for prevalences of 3GC resistance ranging between 10 and 30%. The negative predictive values were 99% for E. coli and K. pneumoniae and 89% for the species producing inducible AmpC beta-lactamase. In conclusion, the ␤Lacta test was found to be easy to use and efficient for the prediction of resistance to third-generation cephalosporins, particularly in extended-spectrum beta-lactamase-producing strains.

show abstract

Evaluation of the βLACTA Test, a Novel Commercial Chromogenic Test for Rapid Detection of Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates

Cited by 10 publications

References 15 publications

Early detection with the β-LACTA™ test of extended-spectrum β-lactamase–producing Enterobacteriaceae in blood cultures

Early detection with the β-LACTA™ test of extended-spectrum β-lactamase–producing Enterobacteriaceae in blood cultures

Clinical Impact of MALDI-TOF MS Identification and Rapid Susceptibility Testing on Adequate Antimicrobial Treatment in Sepsis with Positive Blood Cultures

Evaluation of the βLacta Test, a Rapid Test Detecting Resistance to Third-Generation Cephalosporins in Clinical Strains of Enterobacteriaceae

Contact Info

Product

Resources

About